Synchronous | Metachronous | P-value | ||
---|---|---|---|---|
(N = 144) | (N = 70) | |||
Age (years, min-max) | 59.0 (26.0–81.0) | 56.0 (33.0–76.0) | 0.232a | |
Gender | Male | 118 (81.9) | 48 (68.6) | 0.028b |
Female | 26 (18.1) | 22 (31.4) | ||
Nephrectomy | Yes | 52 (36.6) | 69 (100.0) | <.001b |
Treatment free interval | ≥1 yr | 8 (5.6) | 48 (68.6) | <.001c |
< 1 yr | 136 (94.4) | 22 (31.4) | ||
Anemia | 111 (77.1) | 59 (84.3) | 0.221b | |
Hypercalcemia | 20 (14.4) | 8 (11.6) | 0.578b | |
Neutrophilia | 21 (15.1) | 12 (17.7) | 0.639b | |
Elevated LDH | >×1.5ULN | 39 (38.2) | 10 (23.3) | 0.082b |
KPS | > 80 | 135 (97.1) | 69 (100) | 0.304c |
≤ 80 | 4 (2.9) | 0 (0) | ||
Thrombocytosis | > 400 K | 18 (12.5) | 4 (5.7) | 0.125b |
First line therapy | Immunotherapy | 89 (61.8) | 37 (52.9) | 0.212b |
Targeted therapy | 55 (38.2) | 33 (47.1) | ||
Heng risk | Intermediate | 107 (74.3) | 64 (91.4) | 0.003b |
Poor | 37 (25.7) | 6 (8.6) | ||
Tumor (T) | T1 - T2 | 70 (67.3) | 26 (49.1) | 0.027b |
T3 -T4 | 34 (32.7) | 27 (50.9) | ||
Lymph node(N) | N0 | 49 (47.1) | 5 (20.0) | <.001b |
N1 | 25 (24.0) | 20 (80.0) | ||
Nx | 30 (28.9) | 0 (0.0) | ||
Fuhrman nuclear grade | G1-G2 | 30 (33) | 11 (21.6) | 0.151b |
G3-G4 | 61 (67) | 40 (78.4) | ||
Histology | Clear cell | 113 (96.6) | 51 (86.4) | 0.022c |
Non-clear cell | 4 (3.4) | 8 (13.6) | ||
Treatment duration (Month) | 3.4 (1.0–70.4) | 5.3 (1.0–62.0) | 0.058a | |
Follow-up duration (Month) | 81.3 (4.8–141.5) | 142.3 (9.4–147.6) | 0.005d | |
Progression free survival (Month, median(95%CI)) | 4.4 (3.1–5.2) | 5.9 (4.1–9.5) | 0.044d | |
Cancer specific survival (Month, median(95%CI)) | 9.6 (7.4–13.8) | 21.3 (15.1–29.3) | <.001d |